Table 1.

Baseline patient characteristics from RESPOND-2

Characteristics	N = 403
Gender – no. (%)
Male	268 (67)
Female	135 (33)
Age – years
Mean	52.7
Standard Deviation	7.7
Range	26–74
Race – no. (%)
Black	49 (12)
Non-Black	354 (88)
Prior Treatment Experience – no. (%)*
Non-Responders	144 (36)
Relapsers	259 (64)
Baseline METAVIR Score – no. (%)†
F0 – no fibrosis	18 (4)
F1 – portal fibrosis without septa	200 (50)
F2 – portal fibrosis with few septa	79 (20)
F3 – numerous septa without cirrhosis	29 (7)
F4 – cirrhosis	49 (12)
Missing‡	28 (7)

^*Prior nonresponders had a decrease in plasma HCV-RNA of at least 2-log₁₀ by week 12 of prior therapy but with detectable HCV-RNA throughout the course of therapy. Prior relapsers had undetectable HCV-RNA at end of prior therapy without subsequent attainment of a sustained virologic response.

^†A central pathologist determined fibrosis score. Twenty-eight patients had missing data.

^‡Patients with missing METAVIR score were not included in the model.